Drug Trial Radar · NCT04302025
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
99
Planned (sponsor's estimate)
Start
Nov 6, 2020
Primary completion
Nov 30, 2026
Study completion May 30, 2030
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
Conditions
- Non-small Cell Lung Cancer
Interventions
AlectinibDrug
Participants will receive oral alectinib twice per day (BID).
EntrectinibDrug
Participants will receive oral entrectinib daily.
VemurafenibDrug
Participants will receive oral vemurafenib BID.
CobimetinibDrug
Participants will receive oral cobimetinib daily.
PralsetinibDrug
Participants will receive oral pralsetinib daily.
AtezolizumabDrug
Atezolizumab will be administered by intravenous (IV) infusion.
SBRTDrug
Participants will receive SBRT given concurrently, starting with the first dose of atezolizumab.
ResectionProcedure
Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC.
ChemotherapyDrug
Participants will receive SOC chemotherapy as determined by the treating physician.
DivarasibDrug
Participants in the KRAS G12C cohort will receive oral divarasib for approximately 8 weeks until the day before surgery as neoadjuvant therapy up to 3 years as adjuvant therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)Time frame: After surgical resection (approximately study Week 8)
- Checkpoint Inhibitor (CPI) Cohort: Pathological Complete Response (pCR)Time frame: After surgical resection (approximately study Week 8)
- KRAS G12C Cohort: Percentage of Participants With 3-5 Grade Adverse Events (AEs)Time frame: After surgical resection (approximately study Week 8)
- KRAS G12C Cohort: Percentage of Participants Without Delays of Surgery due to Treatment-related AEs as Reported by the InvestigatorTime frame: After surgical resection (approximately study Week 8)
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
University of California Los Angeles - Jonsson Comprehensive Cancer Center
Los Angeles, California
The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange
Orange, California
UC Davis Comprehensive Cancer Center
Sacramento, California
Yale Cancer Center
New Haven, Connecticut
MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)
Washington D.C., District of Columbia
Moffitt Cancer Center
Tampa, Florida
Northwestern University
Chicago, Illinois
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
Ellis Fischel Cancer Center
Columbia, Missouri
Siteman Cancer Center - Washington University Medical Campus
St Louis, Missouri
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Laura and ISAAC Perlmutter Cancer Center at NYU Langone.
New York, New York
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Ohio State University
Columbus, Ohio
AHN Cancer Institute ? Allegheny General Hospital
Pittsburgh, Pennsylvania
Baptist Clinical Research Institute
Memphis, Tennessee
University of Texas MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists (Fairfax) - USOR
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.